HPAC

The HPAC cell line, derived from human pancreatic ductal adenocarcinoma, serves as an essential model for studying pancreatic cancer's molecular and cellular characteristics. Known for its utility in evaluating the impact of various chemotherapeutic agents and signaling pathways, HPAC cells exhibit key features typical of pancreatic cancer, including resistance mechanisms. Recent studies involving HPAC have focused on understanding drug resistance, particularly to erlotinib, a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR). Research has demonstrated that resistance to erlotinib in HPAC cells is associated with significant metabolic alterations, such as changes in phospholipid and amino acid metabolism. Specifically, increased levels of short-chain acylcarnitines and changes in glycerophospholipid profiles have been linked to an elevated metabolic state in erlotinib-resistant HPAC cells. HPAC cells also express matrix metalloproteinases (MMPs), particularly MT1-MMP, which is crucial for their invasive behavior. The Wnt/β-catenin signaling pathway has been implicated in regulating MMP expression, contributing to the cell's migration and invasion potential. The application of compounds like matrine has been shown to inhibit HPAC cell migration by downregulating MT1-MMP through the suppression of Wnt/β-catenin signaling. These attributes highlight HPAC as a pivotal cell line for exploring therapeutic interventions aimed at mitigating pancreatic cancer's aggressive and treatment-resistant nature. Pancreas cancer cell lines, Pancreas, Adenocarcinoma, Growth Conditions: Adherent, Biosafety level: BSL 1